Under the agreement, Sanity Group will contribute its pharmaceutical know-how, intellectual property and experience in building clinically relevant cannabinoid products across global markets, while Curaleaf Laboratories will leverage its MHRA-approved infrastructure and compliance framework to support the introduction of new formulations.
Finn Hänsel, Founder and Managing Director of Sanity Group: “The UK is a key strategic market for medical cannabis. Partnering with Curaleaf Laboratories allows us to translate our capabilities into scalable, compliant products that can make a meaningful difference for patients and prescribing clinicians.”
Richard Hodgson, Managing Director of Curaleaf Laboratories: “This partnership represents a significant step forward in our mission to deliver consistent, pharmaceutical-grade medical cannabis products to patients in the UK. By working with Sanity Group, we are combining complementary strengths to accelerate innovation while maintaining the highest standards of quality, safety, and regulatory compliance.”
This partnership underscores the continued maturation of the UK medical cannabis market and reflects a shared vision to set new benchmarks for quality, innovation, and patient-centric care. The first Sanity Group products manufactured under this partnership will be available on prescription by clinicians listed on the UK Specialist Register from Q1 2026.
+++
If you are an interested healthcare professional seeking information on prescribing or ordering, please contact Curaleaf at info@curaleaflaboratories.co.uk.
Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.
About Sanity Group
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com/press.
About Curaleaf Laboratories
Curaleaf Laboratories is one of the UK-leading experts in the manufacture and distribution of EU-GMP medical cannabis. With a state-of-the-art MHRA-approved medical cannabis manufacturing facility and a comprehensive quality management system, Curaleaf Laboratories is meeting the growing patient demand for a consistent range of medical cannabis manufactured to EU-GMP standards, with varying novel dosage forms and levels of cannabinoid content. Part of the Curaleaf International group since 2019, Curaleaf Laboratories has evolved from a well-established specials medicines manufacturer with over a decade of expertise in unlicensed medicines. With that experience, Curaleaf Laboratories is widening access to clinics and pharmacies all across the UK, while leading the market as a trusted manufacturer, distributor and partner.
Press Contact
Jennifer Plankenbühler
Press Officer | Lead Medical PR
E-Mail: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com
Phone: +49 (0) 173 37 62 845
